To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours

NCT01951846 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

61

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Solid Tumour

Interventions

DRUG: BIBF 1120

Sponsor

Boehringer Ingelheim